We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma.
- Authors
Mair, Maximilian J.; Ilhan-Mutlu, Ayseguel; Pajenda, Sahra; Kiesel, Barbara; Wöhrer, Adelheid; Widhalm, Georg; Dieckmann, Karin; Marosi, Christine; Wagner, Ludwig; Preusser, Matthias; Berghoff, Anna S.
- Abstract
Purpose: In primary brain tumors, the efficacy of immune-modulating therapies is still under investigation as inflammatory responses are restricted by tight immunoregulatory mechanisms in the central nervous system. Here, we measured soluble PD-L1 (sPD-L1) in the plasma of patients with recurrent glioblastoma (GBM) and recurrent WHO grade II–III glioma treated with bevacizumab-based salvage therapy. Methods: Thirty patients with recurrent GBM and 10 patients with recurrent WHO grade II–III glioma were treated with bevacizumab-based salvage therapy at the Medical University of Vienna. Prior to each treatment cycle, EDTA plasma was drawn and sPD-L1 was measured applying a sandwich ELISA with a lower detection limit of 0.050 ng/ml. Leukocyte counts and C-reactive protein (CRP) levels were measured according to institutional practice. Results: Median number of sPD-L1 measurements was 6 per patient (range: 2–24). At baseline, no significant difference in sPD-L1 concentrations was observed between WHO grade II–III glioma and GBM. Intra-patient variability of sPD-L1 concentrations was significantly higher in WHO grade II–III glioma than in GBM (p = 0.014) and tendentially higher in IDH-mutant than in IDH-wildtype glioma (p = 0.149) In WHO grade II–III glioma, sPD-L1 levels were significantly lower after one administration of bevacizumab than at baseline (median: 0.039 ng/ml vs. 0.4855 ng/ml, p = 0.036). In contrast, no significant change could be observed in patients with GBM. Conclusions: Changes in systemic inflammation markers including sPD-L1 are observable in patients with recurrent glioma under bevacizumab-based treatment and differ between WHO grade II–III glioma and GBM.
- Subjects
MEDIZINISCHE Universitat Wien; BRAIN tumors; GLIOMAS; PROGRAMMED death-ligand 1; LEUKOCYTE count; CENTRAL nervous system; GLIOBLASTOMA multiforme
- Publication
Cancer Immunology, Immunotherapy, 2021, Vol 70, Issue 12, p3643
- ISSN
0340-7004
- Publication type
Article
- DOI
10.1007/s00262-021-02951-2